Company intelligence / Profile preview
Dx&Vx
Seoul, South Koreadxvx.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Dx&Vx has completed Phase 1 clinical trials of its universal COVID‑19 VLP-based vaccine in the US and South Africa, showing safety and immunogenicity. The company is preparing global Phase 2 studies. Its pipeline includes a next-gen mRNA platform with room-temperature stability, an oral obesity drug candidate, a cancer vaccine program (“OVM‑200”), anti-cancer monoclonal antibodies in preclinical development, and microbiome/probiotic products.
- Therapeutic areas
- OncologyPulmonologyEndocrinologyMetabolic DisordersInfectious Diseases
- Modalities
- mRNA-based drugsMonoclonal antibodySmall moleculeRNA therapyVaccineProbiotic/Live biotherapeutic product therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Hanmi Pharmaceutical GroupGenScript ProBioGlobal pharma giant via MTA for mRNA platform evaluation
Beyond the preview
Go deeper on Dx&Vx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dx&Vx.